Pular para conteúdo

Doença de células falciformes (pediatria)

Prevenção de Crises\_

Indução farmacológica da hemoglobina fetal

Pharmacotherapy in sickle cell disease—state of the art and future prospects. (abre nova janela)

Hankins J, Aygun B.

Fonte‎: Br J Haematol 2009;145(3):296-308.

Indexado‎: PubMed 19222472

DOI‎: 10.1111/j.1365-2141.2009.07602.x

https://www.ncbi.nlm.nih.gov/pubmed/19222472 (abre nova janela)

Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. (abre nova janela)

Hankins JS, Ware RE, Rogers ZR, Wynn LW, Lane PA, Scott JP, Wang WC.

Fonte‎: Blood 2005;106(7):2269-75.

Indexado‎: PubMed 16172253

DOI‎: 10.1182/Blood-2004-12-4973

https://www.ncbi.nlm.nih.gov/pubmed/16172253 (abre nova janela)

Hydroxyurea dose escalation for sickle cell anemia in sub-Saharan Africa. (abre nova janela)

John CC, Opoka RO, Latham TS, Hume HA, Nabaggala C, Kasirye P, Ndugwa CM, Lane A, Ware RE

Fonte‎: N Engl J Med 2020;382(26):2524-33.

Indexado‎: PubMed 32579813

DOI‎: 10.1056/NEJMoa2000146

https://www.ncbi.nlm.nih.gov/pubmed/32579813 (abre nova janela)

The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. (abre nova janela)

Lobo CL, Pinto JF, Nascimento EM, Moura PG, Cardoso GP, Hankins JS.

Fonte‎: Br J Haematol 2013;161(6):852-60.

Indexado‎: PubMed 23590693

DOI‎: 10.1111/bjh.12323

https://www.ncbi.nlm.nih.gov/pubmed/23590693 (abre nova janela)

Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries. (abre nova janela)

Mulaku M, Opiyo N, Karumbi J, Kitonyi G, Thoithi G, English M.

Fonte‎: Arch Dis Child 2013;98(11):908-14.

Indexado‎: PubMed 23995076

DOI‎: 10.1136/archdischild-2012-302387

https://www.ncbi.nlm.nih.gov/pubmed/23995076 (abre nova janela)

Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. (abre nova janela)

Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H, Witkop C, Wilson RF, Bass EB, Segal JB.

Fonte‎: Pediatrics 2008;122(6):1332-42.

Indexado‎: PubMed 19047254

DOI‎: 10.1542/peds.2008-0441

https://www.ncbi.nlm.nih.gov/pubmed/19047254 (abre nova janela)

Impact of hydroxyurea on clinical events in the BABY HUG trial. (abre nova janela)

Thornburg CD, Files BA, Luo Z, Miller ST, Kalpatthi R, Iyer R, Seaman P, Lebensburger J, Alvarez O, Thompson B, Ware RE, Wang WC; BABY HUG Investigators.

Fonte‎: Blood 2012;120(22):4304-10.

Indexado‎: PubMed 22915643

DOI‎: 10.1182/blood-2012-03-419879

https://www.ncbi.nlm.nih.gov/pubmed/22915643 (abre nova janela)

Hydroxyurea for children with sickle cell anemia in sub-Saharan Africa. (abre nova janela)

Tshilolo L, Tomlinson G, Williams TN, Santos B, Olupot-Olupot P, Lane A, Aygun B, Stuber SE, Latham TS, McGann PT, Ware RE; REACH Investigators

Fonte‎: N Engl J Med 2019;380(2):121-31.

Indexado‎: PubMed 30501550

DOI‎: 10.1056/NEJMoa1813598

https://www.ncbi.nlm.nih.gov/pubmed/30501550 (abre nova janela)

Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. (abre nova janela)

Wang WC, Helms RW, Lynn HS, Redding-Lallinger R, Gee BE, Ohene-Frempong K, Smith-Whitley K, Waclawiw MA, Vichinsky EP, Styles LA, Ware RE, Kinney TR.

Fonte‎: J Pediatr 2002;140(2):225-9.

Indexado‎: PubMed 11865275

DOI‎: 10.1067/mpd.2002.121383

https://www.ncbi.nlm.nih.gov/pubmed/11865275 (abre nova janela)

Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. (abre nova janela)

Wang WC, Oyeku SO, Luo Z, Boulet SL, Miller ST, Casella JF, Fish B, Thompson BW, Grosse SD; BABY HUG Investigators.

Fonte‎: Pediatrics 2013;132(4):677-83.

Indexado‎: PubMed 23999955

DOI‎: 10.1542/peds.2013-0333

https://www.ncbi.nlm.nih.gov/pubmed/23999955 (abre nova janela)

Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). (abre nova janela)

Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW; for the BABY HUG investigators.

Fonte‎: Lancet 2011;377(9778):1663-72.

Indexado‎: PubMed 21571150

DOI‎: 10.1016/S0140-6736(11)60355-3

https://www.ncbi.nlm.nih.gov/pubmed/21571150 (abre nova janela)

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. (abre nova janela)

Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, Odame I, Fuh B, George A, Owen W, Luchtman-Jones L, Rogers ZR, Hilliard L, Gauger C, Piccone C, Lee MT, Kwiatkowski JL, Jackson S, Miller ST, Roberts C, Heeney MM, Kalfa TA, Nelson S, Imran H, Nottage K, Alvarez O, Rhodes M, Thompson AA, Rothman JA, Helton KJ, Roberts D, Coleman J, Bonner MJ, Kutlar A, Patel N, Wood J, Piller L, Wei P, Luden J, Mortier NA, Stuber SE, Luban NL, Cohen AR, Pressel S, Adams RJ.

Fonte‎: Lancet 2016;387(10019):661-70.

Indexado‎: PubMed 26670617

https://www.ncbi.nlm.nih.gov/pubmed/26670617 (abre nova janela)

How I use hydroxyurea to treat young patients with sickle cell anemia. (abre nova janela)

Ware RE.

Fonte‎: Blood 2010;115(26):5300-11.

Indexado‎: PubMed 20223921

DOI‎: 10.1182/blood-2009-04-146852

https://www.ncbi.nlm.nih.gov/pubmed/20223921 (abre nova janela)

Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. (abre nova janela)

Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE.

Fonte‎: Blood 2004;103(6):2039-45.

Indexado‎: PubMed 14630791

DOI‎: 10.1182/blood-2003-07-2475

https://www.ncbi.nlm.nih.gov/pubmed/14630791 (abre nova janela)

Prevenção de infecções e outras complicações

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. (abre nova janela)

Hirst C, Owusu-Ofori S.

Fonte‎: Cochrane Database Syst Rev 2012;(9):CD003427.

Indexado‎: PubMed 22972063

DOI‎: 10.1002/14651858.CD003427.pub2

https://www.ncbi.nlm.nih.gov/pubmed/22972063 (abre nova janela)

Sickle cell disease. (abre nova janela)

Meremikwu MM, Okomo U.

Fonte‎: BMJ Clin Evid 2011;02:2402.

Indexado‎: PubMed 21718552

https://www.ncbi.nlm.nih.gov/pubmed/21718552 (abre nova janela)

A phase 3 trial of l-glutamine in sickle cell disease. (abre nova janela)

Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP

Fonte‎: N Engl J Med 2018;379(3):226-35.

Indexado‎: PubMed 30021096

DOI‎: 10.1056/NEJMoa1715971

https://www.ncbi.nlm.nih.gov/pubmed/30021096 (abre nova janela)

Malaria chemoprophylaxis in sickle cell disease. (abre nova janela)

Oniyangi O, Omari AA.

Fonte‎: Cochrane Database Syst Rev 2006;(4):CD003489.

Indexado‎: PubMed 17054173

DOI‎: 10.1002/14651858.CD003489.pub2

https://www.ncbi.nlm.nih.gov/pubmed/17054173 (abre nova janela)